Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma, Kaposi 3Neoplasms 3Breast Neoplasms 3Acquired Immunodeficiency Syndrome 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2HIV Infections 2Glioma 2Glioblastoma 2Endometrial Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Weight Loss 1Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytopenia 1Splenomegaly 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Ritonavir × Clear all
NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
862 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡